RIGLHIGH SIGNALOPERATIONAL10-K

RIGL substantially expanded revenue while notably reducing its total debt burden and liability position, though cash reserves declined meaningfully.

The company appears to have achieved substantial commercial growth while simultaneously deleveraging its balance sheet, suggesting improved operational performance and financial discipline. However, the decline in cash reserves alongside increased current liabilities indicates potential working capital pressures that warrant monitoring, particularly given the company's dependence on its commercial products for growth.

Comparing 2026-03-03 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

RIGL demonstrated strong top-line growth with revenue substantially higher year-over-year, accompanied by a notable increase in R&D spending that suggests continued investment in its pipeline. The balance sheet showed mixed signals - while total liabilities and debt both declined meaningfully, current liabilities increased and cash reserves fell by nearly 30%, partially offset by higher accounts receivable and substantially increased inventory levels. Overall, the financial picture suggests a company experiencing significant commercial momentum while managing through a period of working capital intensity.

FINANCIAL STATEMENT CHANGES
Inventory
Balance Sheet
+91.7%
$6.0M→$11.5M

Inventory surged 91.7% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+77.8%
$135.1M→$240.2M

Current assets grew 77.8% — improving short-term liquidity or inventory/receivables build.

Revenue
P&L
+64.1%
$179.3M→$294.3M

Strong top-line growth of 64.1% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+56.8%
$63.3M→$99.2M

Current liabilities surged 56.8% — significant near-term obligations; verify ability to meet short-term debt.

R&D Expense
P&L
+42.4%
$23.4M→$33.3M

R&D investment increased 42.4% — signals commitment to future product development, though near-term margin impact.

Cash & Equivalents
Balance Sheet
-28.5%
$56.7M→$40.6M

Cash decreased 28.5% — monitor burn rate and upcoming capital needs.

Capital Expenditure
Cash Flow
-28.2%
$627K→$450K

Capex reduced 28.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
+24.4%
$41.6M→$51.8M

Receivables grew 24.4% — monitor days sales outstanding for collection efficiency.

Total Liabilities
Balance Sheet
-24%
$160.7M→$122.1M

Liabilities reduced 24% — deleveraging improves balance sheet strength and financial flexibility.

Total Debt
Balance Sheet
-12.5%
$60.0M→$52.5M

Debt reduced 12.5% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-03-04
ADDED
As of February 25, 2026, there were 18,473,130 shares of the registrant s common stock outstanding.
Our prospects are highly dependent on our existing commercial products.
TAVALISSE (fostamatinib disodium hexahydrate) is our first FDA-approved product and is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Japan, the Republic of Korea (Korea), Canada and Israel (as TAVALISSE) for the treatment of chronic ITP in adult patients.
REZLIDHIA (olutasidenib) is our second FDA-approved product and indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
W e in-licensed REZLIDHIA from Forma Therapeutics, Inc., now Novo Nordisk (Forma), with exclusive, worldwide rights for its development, manufacturing and commercialization, pursuant to a license and transition services agreement entered in July 2022.
GAVRETO is also approved under accelerated approval based on overall response rate and duration response rate, for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
We acquired the rights to research, develop, manufacture and commercialize GAVRETO in the US from Blueprint Medicines Corporation, now a Sanofi SA company (Blueprint), pursuant to an asset purchase agreement entered in February 2024.
Our development pipeline includes R289, our dual interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor program, which is being advanced in an open-label, Phase 1b study to determine the safety, tolerability and preliminary efficacy of the drug in patients with lower-risk myelodysplastic syndrome (MDS) who are relapsed, refractory or resistant to prior therapies.
We also have a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development that is being led by our partner Eli Lilly and Company (Lilly).
REMOVED
As of February 25, 2025, there were 17,862,958 shares of the registrant s common stock outstanding.
Our prospects are highly dependent on our existing commercial products, TAVALISSE (fostamatinib disodium hexahydrate), REZLIDHIA (olutasidenib), and GAVRETO (pralsetinib).
TAVALISSE (fostamatinib disodium hexahydrate) is our first product approved by the FDA.
TAVALISSE is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Canada, Israel and Japan (as TAVALISSE) for the treatment of chronic ITP in adult patients.
REZLIDHIA (olutasidenib) is o ur second FDA-approved product.
REZLIDHIA capsules are indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
W e in-licensed REZLIDHIA from Forma Therapeutics, Inc., now Novo Nordisk (Forma), with exclusive, worldwide rights for its development, manufacturing and commercialization.
We acquired the rights to research, develop, manufacture and commercialize GAVRETO in the US from Blueprint Medicines Corporation (Blueprint) pursuant to an Asset Purchase Agreement entered in February 2024.
We continue to advance the development of R289, our dual interleukin receptor-associated kinases 1 and 4 (IRAK 1/4) inhibitor program, in an open-label, Phase 1b study to determine the tolerability and preliminary efficacy of the drug in patients with lower-risk myelodysplastic syndrome (MDS) who are relapsed, refractory or resistant to prior therapies.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →